Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Baron Health Care Fund outperformed its benchmark in Q4 2025 with a 13.10% return, driven by biotechnology gains and selective positioning. The manager remains highly optimistic about 2026 due to a massive resurgence in biotech funding, active M&A, and easing regulatory hurdles.
Full Quick Take
Baron Health Care Fund outperformed its benchmark in Q4 2025 with a 13.10% return, driven by biotechnology gains and selective positioning. The manager remains highly optimistic about 2026 due to a massive resurgence in biotech funding, active M&A, and easing regulatory hurdles.
The Aristotle Small Cap Equity Fund posted a 1.96% return in Q4 2025, slightly lagging its benchmark due to tactical healthcare underweights. The manager remains constructive on the asset class, leveraging a bottom-up quality approach to exploit historically cheap small-cap valuations.
Full Quick Take
The Aristotle Small Cap Equity Fund posted a 1.96% return in Q4 2025, slightly lagging its benchmark due to tactical healthcare underweights. The manager remains constructive on the asset class, leveraging a bottom-up quality approach to exploit historically cheap small-cap valuations.
The fund seeks to capitalize on the historically large valuation gap between small-cap and large-cap equities. By targeting well-capitalized, cash-generating small-caps trading at deep discounts to net asset value, the managers expect accelerated capital deployment through corporate actions, acquisitions, and leveraged buyouts, driven by a highly favorable regulatory shift in 2025.
Full Quick Take
The fund seeks to capitalize on the historically large valuation gap between small-cap and large-cap equities. By targeting well-capitalized, cash-generating small-caps trading at deep discounts to net asset value, the managers expect accelerated capital deployment through corporate actions, acquisitions, and leveraged buyouts, driven by a highly favorable regulatory shift in 2025.
